• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

柏林化脓性链球菌分离株中的抗菌药物耐药性

Antimicrobial resistance in Streptococcus pyogenes isolates in Berlin.

作者信息

Arvand M, Hoeck M, Hahn H, Wagner J

机构信息

Institut für Infektionsmedizin, Universitätsklinikum Benjamin Franklin, Freie Universität Berlin, Germany.

出版信息

J Antimicrob Chemother. 2000 Oct;46(4):621-4. doi: 10.1093/jac/46.4.621.

DOI:10.1093/jac/46.4.621
PMID:11020262
Abstract

A total of 212 clinical Streptococcus pyogenes isolates were tested for susceptibility to various antibiotics by agar dilution. The overall frequency of erythromycin resistance was 12.7%, being higher in isolates from children (18.9%) than in those from adult patients (10.7%). Similar results were found for clarithromycin, while 2.8% of the isolates were resistant to ciprofloxacin. All strains were susceptible to penicillin and cefotaxime. Of the erythromycin-resistant isolates subjected to the double-disc diffusion test for erythromycin and clindamycin, 35% expressed constitutive and 55% inducible resistance to clindamycin. Ten per cent were susceptible to clindamycin (M-phenotype). Thus, a high rate of macrolide resistance in S. pyogenes has emerged in Berlin.

摘要

通过琼脂稀释法对总共212株临床分离的化脓性链球菌进行了多种抗生素敏感性测试。红霉素耐药的总体发生率为12.7%,儿童分离株中的发生率(18.9%)高于成年患者分离株(10.7%)。克拉霉素的结果相似,而2.8%的分离株对环丙沙星耐药。所有菌株对青霉素和头孢噻肟敏感。在对红霉素和克林霉素进行双碟扩散试验的红霉素耐药分离株中,35%表现为对克林霉素的组成型耐药,55%表现为诱导型耐药。10%对克林霉素敏感(M表型)。因此,柏林出现了化脓性链球菌中较高的大环内酯耐药率。

相似文献

1
Antimicrobial resistance in Streptococcus pyogenes isolates in Berlin.柏林化脓性链球菌分离株中的抗菌药物耐药性
J Antimicrob Chemother. 2000 Oct;46(4):621-4. doi: 10.1093/jac/46.4.621.
2
High prevalence of erythromycin-resistant, clindamycin/miocamycin-susceptible (M phenotype) Streptococcus pyogenes: results of a Spanish multicentre study in 1998. Spanish Group for the Study of Infection in the Primary Health Care Setting.红霉素耐药、克林霉素/米诺卡霉素敏感(M表型)化脓性链球菌的高流行率:1998年西班牙多中心研究结果。西班牙初级卫生保健环境感染研究小组
J Antimicrob Chemother. 2000 May;45(5):605-9. doi: 10.1093/jac/45.5.605.
3
Emergence of Streptococcus pyogenes strains resistant to erythromycin in Gipuzkoa, Spain.西班牙吉普斯夸省耐红霉素化脓性链球菌菌株的出现。
Eur J Clin Microbiol Infect Dis. 1998 Jan;17(1):25-31. doi: 10.1007/BF01584359.
4
Erythromycin resistance of Streptococcus pyogenes in Madrid.马德里化脓性链球菌的红霉素耐药性
Pediatr Infect Dis J. 1998 Jun;17(6):470-3. doi: 10.1097/00006454-199806000-00006.
5
[Phenotypic characterization of erythromycin resistance in strains of the genus Streptococcus isolated from clinical specimens].[从临床标本中分离出的链球菌属菌株对红霉素耐药性的表型特征分析]
Rev Esp Quimioter. 1998 Sep;11(3):216-20.
6
[Streptococcus pyogenes: penicillin and erythromycin susceptibility in the cities of Neuquen and Cipolletti].[化脓性链球菌:内乌肯市和奇波利蒂市对青霉素和红霉素的敏感性]
Medicina (B Aires). 2000;60(4):487-90.
7
Erythromycin resistance in Streptococcus pyogenes in Italy.意大利化脓性链球菌中的红霉素耐药性。
Emerg Infect Dis. 2000 Mar-Apr;6(2):180-3. doi: 10.3201/eid0602.000212.
8
In vitro activity of midecamycin diacetate, a 16-membered macrolide, against Streptococcus pyogenes isolated in France, 1995-1999.1995 - 1999年法国分离的化脓性链球菌对16元大环内酯类药物麦迪霉素二醋酸酯的体外活性
Clin Microbiol Infect. 2001 Jul;7(7):362-6. doi: 10.1046/j.1198-743x.2001.00280.x.
9
The emergence of erythromycin-resistant Streptococcus pyogenes in Seoul, Korea.
J Infect Chemother. 2001 Jun;7(2):81-6. doi: 10.1007/s101560100013.
10
Incidence of erythromycin resistance in Streptococcus pyogenes: a 10-year study.化脓性链球菌对红霉素的耐药率:一项为期10年的研究。
Diagn Microbiol Infect Dis. 1999 Apr;33(4):255-60. doi: 10.1016/s0732-8893(98)00155-2.

引用本文的文献

1
Group A Antibiotic Resistance in Iranian Children: A Meta-analysis.A组 伊朗儿童的抗生素耐药性:一项荟萃分析。
Oman Med J. 2021 Jan 31;36(1):e222. doi: 10.5001/omj.2020.79. eCollection 2021 Jan.
2
Venom peptides in association with standard drugs: a novel strategy for combating antibiotic resistance - an overview.毒液肽与标准药物联合使用:对抗抗生素耐药性的新策略——综述
J Venom Anim Toxins Incl Trop Dis. 2020 Aug 10;26:e20200001. doi: 10.1590/1678-9199-JVATITD-2020-0001. eCollection 2020.
3
Molecular characterization and evaluation of the emerging antibiotic-resistant Streptococcus pyogenes from eastern India.
印度东部新出现的耐抗生素化脓性链球菌的分子特征及评估
BMC Infect Dis. 2016 Dec 12;16(1):753. doi: 10.1186/s12879-016-2079-9.
4
Antibiotic susceptibility of streptococcus pyogenes isolated from respiratory tract infections in dakar, senegal.从塞内加尔达喀尔呼吸道感染中分离出的化脓性链球菌的抗生素敏感性
Microbiol Insights. 2013 Oct 29;6:71-5. doi: 10.4137/MBI.S12996. eCollection 2013.
5
Macrolide and tetracycline resistance and emm type distribution of Streptococcus pyogenes isolates recovered from Turkish patients.从土耳其患者中分离出的酿脓链球菌对大环内酯类和四环素类的耐药性及 emm 型分布情况。
Microb Drug Resist. 2010 Dec;16(4):279-84. doi: 10.1089/mdr.2010.0021. Epub 2010 Jul 12.
6
Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers.阿奇霉素和克拉霉素对健康志愿者口腔中草绿色链球菌大环内酯类药物敏感性的影响。
Eur J Clin Microbiol Infect Dis. 2008 Nov;27(11):1087-92. doi: 10.1007/s10096-008-0547-x. Epub 2008 May 30.
7
Antimicrobial susceptibility survey of Streptococcus pyogenes isolated in Japan from patients with severe invasive group A streptococcal infections.日本重症侵袭性A组链球菌感染患者中分离出的化脓性链球菌的药敏调查
Antimicrob Agents Chemother. 2005 Feb;49(2):788-90. doi: 10.1128/AAC.49.2.788-790.2005.
8
Clonal relatedness of erythromycin-resistant Streptococcus pyogenes isolates in Germany.德国耐红霉素化脓性链球菌分离株的克隆相关性
Antimicrob Agents Chemother. 2004 Apr;48(4):1369-73. doi: 10.1128/AAC.48.4.1369-1373.2004.
9
Comparison of broth microdilution, E Test, and agar dilution methods for antibiotic susceptibility testing of Campylobacter jejuni and Campylobacter coli.用于空肠弯曲菌和结肠弯曲菌抗生素敏感性测试的肉汤微量稀释法、E测试法和琼脂稀释法的比较
J Clin Microbiol. 2003 Mar;41(3):1062-8. doi: 10.1128/JCM.41.3.1062-1068.2003.